USA Financial Formulas Buys 1,829 Shares of Amgen Inc. $AMGN

USA Financial Formulas bought a new position in Amgen Inc. (NASDAQ:AMGN) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 1,829 shares of the medical research company’s stock, valued at approximately $771,000.

Several other hedge funds have also recently modified their holdings of the business. BlackRock Inc. lifted its holdings in shares of Amgen by 4.8% during the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock valued at $17,874,974,000 after purchasing an additional 2,261,544 shares in the last quarter. State Street Corp boosted its position in shares of Amgen by 38.2% during the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after buying an additional 11,656,755 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Amgen by 12.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company’s stock valued at $1,952,156,000 after buying an additional 605,928 shares during the last quarter. Bank of America Corp DE bought a new stake in Amgen in the 2nd quarter worth about $1,831,903,000. Finally, Amundi increased its holdings in Amgen by 15.2% in the 2nd quarter. Amundi now owns 3,890,189 shares of the medical research company’s stock worth $1,408,715,000 after buying an additional 512,883 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

NASDAQ AMGN opened at $432.49 on Friday. The stock has a market capitalization of $233.82 billion, a price-to-earnings ratio of 26.88, a PEG ratio of 3.17 and a beta of 0.41. Amgen Inc. has a 1-year low of $288.00 and a 1-year high of $447.03. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The business’s fifty day moving average price is $415.54 and its 200-day moving average price is $374.76.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The company had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. During the same quarter in the previous year, the company posted $6.02 earnings per share. Amgen’s revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities analysts predict that Amgen Inc. will post 22.94 earnings per share for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were given a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend was Friday, August 21st. Amgen’s dividend payout ratio (DPR) is presently 62.65%.

Analyst Ratings Changes

A number of brokerages have weighed in on AMGN. Morgan Stanley decreased their target price on Amgen from $362.00 to $359.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 7th. UBS Group raised their price target on shares of Amgen from $430.00 to $470.00 and gave the company a “buy” rating in a report on Friday, October 9th. Scotiabank lifted their price target on shares of Amgen from $450.00 to $500.00 and gave the stock an “outperform” rating in a research note on Monday, September 28th. Jefferies Financial Group reiterated a “hold” rating and issued a $410.00 price target on shares of Amgen in a research note on Wednesday, September 23rd. Finally, Sanford C. Bernstein boosted their price objective on shares of Amgen from $335.00 to $345.00 and gave the company a “market perform” rating in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $387.93.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 2,970 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This represents a 28.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Rachna Khosla sold 2,000 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the completion of the transaction, the senior vice president owned 6,404 shares in the company, valued at $2,642,098.28. This trade represents a 23.80% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 6,222 shares of company stock worth $2,540,926 over the last three months. Insiders own 0.85% of the company’s stock.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.